OakChart

Marker Therapeutics Inc

MRKRHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:53 PM ET

0.9501-0.0002 (-0.02%)
2026-11-12 05:49 CET
Market cap
15.84 USD m
Revenue, TTM
2.34 USD m
Net income, TTM
-8.71 USD m
Free cash flow, TTM
-9.76 USD m
EPS diluted, TTM
-0.48
P/E
-
Compare

Price

MRKR against its 20, 50 and 200-day averages
2050200beatearnings
1.001.201.401.60577K1.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MRKRclose 0.9520-day 0.9950-day 1.07200-day 1.330.9552w low

61.4% under the 52-week high of 2.46 on 8 Jan 2026. 52-week low 0.87 on 14 Nov 2025. Last 15 sessions, 34.5% high to low

Volume 0.24× normal · the line is the 50-bar volume average

Profile

MRKR
52-week range, 5% of the way up
0.872.46

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.

Employees5
IPOJan 05, 1998
Beta1.62
ATR, 14d0.10
Rel volume0.24
Short float1.30%
Insider own19.03%
Inst own10.46%

Snapshot

6 groups

Valuation

Index-
Market Cap15.84M
Enterprise Value3.92M
Income-8.71M
Sales2.34M
Book/sh0.73
Cash/sh0.72
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees5
IPOJan 05, 1998

Ratios

P/E-
Forward P/E-
PEG-
P/S6.77
P/B1.30
P/C1.33
P/FCF-
EV/EBITDA-
EV/Sales1.67
Quick Ratio6.03
Current Ratio6.03
Debt/Eq0.00
LT Debt/Eq0.00
Option/ShortNo / Yes

Earnings

EPS (ttm)-0.48
EPS next Y-0.88
EPS next Q-0.12
EPS this Y24.89%
EPS next Y-47.75%
EPS next 5Y-
EPS past 3/5Y39.48% 33.49%
Sales past 3/5Y0.31% 50.02%
EPS Y/Y TTM64.88%
Sales Y/Y TTM-56.64%
EPS Q/Q67.12%
Sales Q/Q-100.00%
EarningsAug 19
EPS/Sales Surpr.29.13% 5.04%

Ownership

Insider Own19.03%
Insider Trans0.00%
Inst Own10.46%
Inst Trans-0.03%
ROA-59.33%
ROE-76.87%
ROIC-71.57%
Gross Margin-
Oper. Margin-458.56%
Profit Margin-372.69%
SMA20-4.52%
SMA50-11.21%
SMA200-28.45%
Trades-

Technical

Shs Outstand16.67M
Shs Float13.50M
Short Float1.30%
Short Ratio1.50
Short Interest0.18M
52W High2.46 -61.38%
52W Low0.87 9.21%
Volatility11.54% 12.01%
ATR (14)0.10
RSI (14)46.03
Beta1.62
Rel Volume0.24
Avg Volume117.24K
Volume28,414

Performance

Perf Week-5.93%
Perf Month2.72%
Perf Quarter-14.41%
Perf Half Y-33.56%
Perf YTD-36.23%
Perf Year1.97%
Perf 3Y-65.13%
Perf 5Y-93.31%
Perf 10Y-98.04%
Recom1.00
Target Price7.87
Prev Close0.95
Price0.95
Change %-0.02%

Analyst ratings

latest 7 of 7
DateActionAnalystRating changeTargetImplied
Mar 05, 2025InitiatedCCanaccord GenuityBuy$8+742.0%
Mar 25, 2021InitiatedPPiper SandlerOverweight$6+531.5%
Mar 19, 2021InitiatedCCantor FitzgeraldOverweight$6+531.5%
May 12, 2020DowngradePPiper SandlerOverweight → Neutral$5 → $2.50+163.1%
May 30, 2019InitiatedRROTH CapitalBuy
Mar 01, 2019InitiatedJJanneyBuy
Dec 03, 2018UpgradePPiper JaffrayNeutral → Overweight

Peers

Mkt cap
TickerCompanyMkt cap
TCRXTscan Therapeutics Inc12.58M
ATRAAtara Biotherapeutics Inc82.61M
TVGNTevogen Inc39.07M
ESLAEstrella Immunopharma Inc34.53M
ACETAdicet Bio Inc27.99M
GTBPGT Biopharma Inc8.14M
TILInstil Bio Inc42.80M
LYELLyell Immunopharma Inc414.51M
MBIOMustang Bio Inc3.25M
IPSCCentury Therapeutics Inc315.07M

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 200
  • Marker Therapeutics Awarded $2.6 Million FDA Orphan Products Development Grant to Advance MT-601 in Pancreatic Cancer (GlobeNewswire) +15.38%
  • Marker Therapeutics Highlights Expanded Manufacturing Support of CDMO Partner Following Formation of Kincellis Advanced Therapies (GlobeNewswire)
  • Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results (GlobeNewswire)
  • Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
  • Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
  • Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics' MAR-T Cell Technology (GlobeNewswire) -10.95%
  • MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
  • Zacks Industry Outlook Highlights Soleno Therapeutics, Nektar Therapeutics, Rigel Pharmaceuticals, Ironwood Pharmaceuticals and Marker Therapeutics (Zacks) -5.48%
  • MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy? (Zacks) +17.74%
  • 5 Small Drug Stocks to Buy as Industry Recovery Picks Up (Zacks)
  • Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer (GlobeNewswire) +16.23%
  • Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates (GlobeNewswire)
  • Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors (GlobeNewswire)
  • Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-19-0.090-0.127-0.0900.690.663
2026Q12026-05-20-0.160-0.160-0.1600.780.783
2025Q42026-03-18-0.097-0.191-0.1021.100.683
2025Q32025-11-14-0.120-0.360-0.1191.230.722
2025Q22025-08-18-0.250-0.304-0.2880.880.432
2025Q12025-05-16-0.400-0.530-0.4000.350.172
2024Q42025-03-31-0.410-0.220-0.4222.251.222
2024Q32024-11-14-0.260-0.390-0.2591.931.001
2024Q22024-08-14-0.250-0.431-0.2461.17-1
2024Q12024-05-15-0.270-0.250-0.2691.24-1
2023Q42024-03-250.440--0.3080.26--
2023Q32023-11-09-0.340--0.3380.26--
2023Q22023-08-140.290--0.7140.76--
2022Q42023-03-22-0.480-1.000-0.4593.310.001
2022Q32022-11-10-0.800-1.300-0.8283.950.402
2022Q22022-08-11-1.100-1.050-1.1060.792.504

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-4.700-4.780-4.7000.210.00
2020FY-6.100-5.900-6.1030.470.48
2021FY-5.500-5.725-5.4741.240.00
2022FY-3.580-3.600-3.5849.019.00
2023FY-0.940--1.9263.31-
2024FY-1.190-0.730-1.1956.598.33
2025FY-0.790-0.869-0.7903.553.11
2026FY--0.593--4.24
2027FY--0.877--20.19
2028FY-0.523--83.97
2029FY-1.880--164.62
2030FY-5.230--325.47

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-11-023002.120.704.20
2026Q3S2026-10-283102.120.704.20
2026Q3S2026-10-193202.120.704.20
2026Q3S2026-10-163202.120.704.20
2026Q3S2026-08-193202.120.704.20
2026Q3S2026-08-143102.080.604.20
2026Q3S2026-06-023000.680.001.45
2026Q3S2026-05-203100.680.001.45
2026Q3S2026-05-073100.680.001.45
2026Q3S2026-03-193100.680.001.45
2026Q3S2025-12-052001.000.561.45
2026Q3S2025-11-141001.451.451.45
2026Q3S2025-11-111001.451.451.45
2026Q3S2025-11-101001.451.451.45

Estimate history

EPS, annual-11.617-77.498-4.7-6.103-5.474-3.584-1.926-1.195-0.795-0.4806
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.246-0.259-0.422-0.4-0.288-0.119-0.102-0.165-0.095
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0.1830.2060.2130.4671.2423.5143.3116.5913.5472.34
Period201720182019202020212022202320242025TTM
Sales, quarterly1.1691.9262.2520.3490.8611.2331.10300
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual1.064.544.5735.078.318.48.910.716.67316.673
Period201720182019202020212022202320242025MRQ
Shares, quarterly8.98.910.711.21511.31516.67316.67316.67316.673
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue2.343.556.593.313.511.240.470.210.21
Cost of Goods Sold Incl. D&A----3.683.16---
Gross Profit----5.33-1.92---
Selling, General and Administrative Excl. Other13.0515.9817.7117.8923.3037.5628.2822.46148.38
Research and Development8.8111.8013.4710.4211.9727.7918.8812.76124.00
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-10.71-12.44-11.12-14.58-19.79-39.48-28.89-22.53-148.17
Interest Expense0.000.000.000.000.000.000.000.000.00
Unusual Expense0.000.450.000.000.232.41-0.03-0.020.04
Net Income Before Taxes-8.72-12.18-10.68-14.04-19.78-41.88-28.71-21.43-147.96
Income Taxes-0.02-0.020.050.000.000.000.000.000.00
Consolidated Net Income-8.71-12.16-10.73-14.05-19.78-41.88-28.71-21.43-147.96
Net Income From Continuing Operations-8.71-12.16-10.73-14.05-19.78-41.88-28.71-21.43-147.96
Net Income-8.71-12.16-10.73-16.97-29.93-41.88-28.71-21.43-147.96
EPS (Recurring)-0.45-0.77-1.19-1.93-3.56-5.25-6.11-4.70-77.48
EPS (Basic, Before Extraordinaries)-0.48-0.79-1.20-1.93-3.58-5.47-6.10-4.70-77.50
EPS (Diluted)-0.48-0.79-1.20-1.93-3.58-5.47-6.10-4.70-77.50
EBITDA-10.71-12.44-11.12-14.58-19.79-36.32-27.81-22.24-148.17
Non-Operating Income (Expense)1.990.710.440.540.250.010.151.080.25
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.500.420.190.683.315.965.233.9116.35
Price To Sales Ratio12.156.434.2414.636.3258.54146.12615.84514.38
Gross Margin----151.79-154.70---
Operating Margin-458.56-350.68-168.69-440.37-563.28-3,179.32-6,188.25-10,567.28-71,930.07
Net Margin-372.69-342.96-162.82-512.46-851.87-3,372.68-6,149.74-10,050.92-71,826.32
Shares Outstanding16.6716.6710.708.908.408.315.074.574.54
Market Capitalization15.8415.8433.3048.8922.2378.9673.52131.70251.97

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.001.101.230.860.352.251.93
Cost of Goods Sold Incl. D&A0.000.00------
Gross Profit0.000.00------
Selling, General and Administrative Excl. Other2.624.072.993.375.124.506.114.33
Research and Development1.482.842.142.354.183.145.093.47
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.62-4.07-1.88-2.14-4.26-4.16-3.86-2.40
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.450.000.00
Net Income Before Taxes-1.83-3.18-1.72-2.00-4.02-4.45-3.79-2.31
Income Taxes0.000.00-0.020.000.000.000.050.00
Consolidated Net Income-1.83-3.18-1.70-2.00-4.02-4.45-3.84-2.31
Net Income From Continuing Operations-1.83-3.18-1.70-2.00-4.02-4.45-3.84-2.31
Net Income-1.83-3.18-1.70-2.00-4.02-4.45-3.84-2.31
EPS (Recurring)-0.09-0.16-0.10-0.12-0.29-0.37-0.42-0.26
EPS (Basic, Before Extraordinaries)-0.09-0.16-0.10-0.12-0.29-0.40-0.42-0.26
EPS (Diluted)-0.09-0.16-0.10-0.12-0.29-0.40-0.42-0.26
EBITDA-2.62-4.07-1.88-2.14-4.26-4.16-3.86-2.40
Non-Operating Income (Expense)0.790.890.170.140.250.160.070.09
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.200.180.090.030.010.380.040.05
Price To Sales Ratio12.157.857.003.193.962.404.294.66
Operating Margin---170.74-173.30-494.79-1,190.34-171.48-124.60
Net Margin---154.35-162.11-466.28-1,273.60-170.43-119.84
Shares Outstanding16.6716.6716.6716.6711.3111.2110.708.90
Market Capitalization15.8421.6824.8411.5517.3113.1733.3025.16

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments17.0419.1915.1111.7843.5021.3543.9061.755.13
Short Term Receivables1.372.351.032.400.001.000.060.110.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.660.480.992.442.482.061.530.140.05
Total Current Assets19.0722.0217.1316.6245.9824.4145.4962.005.18
Net Property, Plant & Equipment0.000.000.000.0022.1521.200.870.150.00
Total Investments and Advances0.000.000.000.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.000.000.000.00
Other Assets0.000.000.0017.800.000.000.000.000.00
Total Assets19.0722.0217.1334.4268.1445.6146.3662.145.18
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.620.390.200.000.00
Accounts Payable0.791.070.961.105.142.940.992.751.51
Income Tax Payable0.050.100.220.00-----
Other Current Liabilities1.432.291.896.687.143.080.800.050.01
Total Current Liabilities2.273.463.077.7812.906.401.992.801.52
Long Term Debt0.000.000.000.0011.2511.870.280.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.007.040.000.000.000.000.00
Total Liabilities2.273.463.0714.8224.1518.272.272.801.52
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity16.8018.5614.0519.6043.9927.3444.0959.343.66
Total Shareholders Equity16.8018.5614.0519.6043.9927.3444.0959.343.66
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity16.8018.5614.0519.6043.9927.3444.0959.343.66
Total Liabilities & Stockholders Equity19.0722.0217.1334.4268.1445.6146.3662.145.18
Book Value Per Share1.011.731.582.335.295.399.6413.073.45
Tangible Book Value Per Share1.011.731.582.335.295.399.6413.073.45
Full-Time Employees55867564428117
Price to Book Ratio1.303.722.900.981.802.692.994.256.93
Return on Assets-59.20-54.82-54.49-38.57-73.63-62.42-39.50-439.53-167.64
Return on Equity-68.81-65.81-83.47-62.20-117.42-80.37-41.44-469.72-223.15
Return on Invested Capital-72.42-57.82-120.75-152.70-75.82-73.21-48.30-249.34-300.21
Quick Ratio8.396.365.572.143.563.8122.8322.113.40
Current Ratio8.396.365.572.143.563.8122.8322.113.40

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-8.71-12.16-10.73-14.05-19.78-41.88-28.71-21.43-147.96
Depreciation----3.683.161.080.29-
Other Funds (Non Cash)0.520.540.25-5.24-2.435.965.205.34132.44
Funds from Operations-8.19-11.63-10.49-19.29-22.21-32.75-22.43-15.80-15.52
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-1.57-0.39-0.422.85-4.765.473.57-2.481.04
Cash from Operating Activities-9.76-12.01-10.91-16.44-26.97-27.28-18.86-18.28-14.48
Capital Expenditures0.000.000.000.000.00-3.13-10.43-0.37-0.15
Net Assets From Acquisitions0.000.000.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.00-4.950.000.000.000.00
Other Sources0.000.000.0018.660.000.000.000.000.00
Cash from Investing Activities0.000.000.0018.66-4.95-3.13-10.43-0.37-0.15
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock9.869.8614.991.110.2052.566.740.8271.25
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-0.07
Sale of Common Pref Stock9.869.8614.991.110.2052.566.740.8271.32
Proceedsfrom Stock Options9.869.8614.931.010.2052.556.190.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities9.869.8614.991.110.2052.566.740.8271.25
Net Change in Cash0.11-2.154.083.33-31.7222.14-22.55-17.8456.62
Free Cash Flow-9.76-12.01-10.91-16.44-26.97-30.41-29.29-18.66-14.63
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments11.9215.6417.0418.9411.8113.69
Short Term Receivables1.621.381.371.671.672.46
Inventories0.000.000.000.000.000.00
Other Current Assets1.040.420.661.131.280.84
Total Current Assets14.5917.4319.0721.7314.7716.99
Net Property, Plant & Equipment0.000.000.000.000.000.00
Total Investments and Advances0.000.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Other Assets0.000.000.000.000.000.00
Total Assets14.5917.4319.0721.7314.7716.99
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.000.00
Accounts Payable0.591.500.790.951.721.30
Income Tax Payable0.050.050.050.060.060.14
Other Current Liabilities1.782.081.432.332.501.06
Total Current Liabilities2.423.642.273.354.282.50
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities2.423.642.273.354.282.50
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity12.1713.8016.8018.3910.4914.49
Total Shareholders Equity12.1713.8016.8018.3910.4914.49
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity12.1713.8016.8018.3910.4914.49
Total Liabilities & Stockholders Equity14.5917.4319.0721.7314.7716.99
Book Value Per Share0.730.831.011.100.931.29
Tangible Book Value Per Share0.730.831.011.100.931.29
Full-Time Employees--5---
Price to Book Ratio1.301.291.350.961.180.71
Return on Assets-59.33-63.30-59.20-87.60-110.48-82.26
Return on Equity-76.87-77.04-68.81-110.67-144.68-97.30
Return on Invested Capital-15.01-23.04-10.14-10.87-38.28-30.68
Quick Ratio6.034.798.396.503.456.79
Current Ratio6.034.798.396.503.456.79

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-1.83-3.18-1.70-2.00-4.02-4.45
Other Funds (Non Cash)0.200.180.110.030.010.38
Funds from Operations-1.63-3.00-1.59-1.97-4.00-4.07
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-2.091.60-0.31-0.772.12-1.43
Cash from Operating Activities-3.72-1.40-1.90-2.74-1.88-5.50
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.000.009.860.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.000.009.860.000.00
Proceedsfrom Stock Options0.000.000.009.860.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.000.000.009.860.000.00
Net Change in Cash-3.72-1.40-1.907.13-1.88-5.50
Free Cash Flow-3.72-1.40-1.90-2.74-1.88-5.50

Revenue breakdown

CPRIT Pancreatic Grant2025: 573.99K
Cancer Prevention And Research Institute Of Texas, Acute Myeloid Leukemia2024: 4.41M 2025: 900.01K
FDA Grant2024: 519.75K 2025: 118.48K
National Institutes of Health National Cancer Institute Grant2024: 5.82K 2025: 391.31K
National Institutes of Health Small Business Innovation Research2024: 982.18K 2025: 472.21K
National Institutes of Health Small Business Innovation Research For Lymphoma Grant2024: 665.00K 2025: 665.00K
National Institutes of Health Small Business Innovation Research For Pancreatic Cancer2024: 7.18K 2025: 425.67K
United States2024: 6.59M 2025: 3.55M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-301.30%0.2M13.5M107.73K
2026-10-150.81%0.1M13.5M71.18K
2026-09-301.25%0.2M13.5M67.85K
2026-09-151.68%0.2M13.5M65.66K
2026-08-311.03%0.1M13.5M64.84K
2026-08-141.48%0.2M13.5M58.59K
2026-07-311.14%0.2M13.5M61.16K
2026-07-151.19%0.2M13.5M68.06K
2026-06-300.86%0.1M13.5M87.38K
2026-06-151.61%0.2M13.5M98.17K
2026-05-291.51%0.2M13.5M109.24K
2026-05-151.81%0.2M13.5M118.27K
2026-04-301.12%0.2M13.5M150.24K
2026-04-151.40%0.2M13.6M218.02K
2026-03-313.78%0.5M13.6M299.24K
2026-03-134.41%0.6M13.6M330.85K
2026-02-274.80%0.7M13.6M355.88K
2026-02-134.32%0.6M13.6M395.09K
2026-01-301.89%0.3M13.5M378.33K
2026-01-152.29%0.3M13.5M321.97K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-10-198-KCurrent report2026-10-19SEC
2026-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-05-1510-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-048-KCurrent report2026-05-01SEC
2026-03-20DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-03-20ARSAnnual report to security holders. 2025-12-31SEC
2026-03-20DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-01SEC
2026-03-198-KCurrent report2026-03-18SEC
2026-03-1810-KAnnual report pursuant to Section 13 or 15(d)2025-12-31SEC
2026-03-10PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-05-01SEC
2026-02-098-KCurrent report2026-02-09SEC
2025-11-194Statement of changes in beneficial ownership of securities2025-11-17SEC
2025-11-194Statement of changes in beneficial ownership of securities2025-11-17SEC
2025-11-194Statement of changes in beneficial ownership of securities2025-11-17SEC
2025-11-17SCHEDULE 13D/ASEC
2025-11-14SCHEDULE 13G/ASEC
2025-11-148-KCurrent report2025-11-14SEC
2025-11-1310-QQuarterly report pursuant to Section 13 or 15(d)2025-09-30SEC
2025-11-058-KCurrent report2025-10-31SEC
2025-11-044Statement of changes in beneficial ownership of securities2025-10-31SEC
2025-11-043Initial statement of beneficial ownership of securities2025-10-31SEC
2025-11-044Statement of changes in beneficial ownership of securities2025-10-31SEC
2025-10-068-KCurrent report2025-10-06SEC
2025-08-268-KCurrent report2025-08-26SEC
2025-08-20SCHEDULE 13D/ASEC
2025-08-19SCHEDULE 13D/ASEC
2025-08-18SCHEDULE 13D/ASEC
2025-08-1410-QQuarterly report pursuant to Section 13 or 15(d)2025-06-30SEC
2025-08-128-KCurrent report2025-08-07SEC
2025-08-05424B7SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
NEA Management Company, LLC9.75%
Blue Owl Capital Holdings LP3.32%
VANGUARD CAPITAL MANAGEMENT LLC2.56%
Aisling Capital Management LP1.95%
RENAISSANCE TECHNOLOGIES LLC1.50%
GEODE CAPITAL MANAGEMENT, LLC0.84%
OSAIC HOLDINGS, INC.0.68%
VANGUARD FIDUCIARY TRUST CO0.52%
LPL Financial LLC0.50%
Concurrent Investment Advisors, LLC0.41%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND1.79%
VANGUARD EXTENDED MARKET INDEX FUND0.77%
Fidelity Extended Market Index Fund0.43%
Fidelity Series Total Market Index Fund0.12%
Fidelity Total Market Index Fund0.08%
Fidelity Nasdaq Composite Index Fund0.02%

OakChart. MRKR. Cached 15 minutes.

Some panels did not load: insider.